GENEVA — An estimated 10.6 million people developed tuberculosis (TB) worldwide in 2025, while approximately 1.1 million died from the disease, according to the World Health Organization’s (WHO) Global Tuberculosis Report 2026.
The latest figures show continued progress in reducing TB deaths, but the pace remains too slow to meet major global targets. WHO says domestic funding for TB programmes rose by 14% to US$5.6 billion between 2024 and 2025, helping offset a decline in international financing. However, substantial gaps remain in diagnosis, treatment, prevention and research.
Progress Has Not Yet Matched Global Targets
TB deaths have fallen by 35% since 2015, and treatment is estimated to have saved 86 million lives since 2000. WHO says the world has reached the first mortality milestone of its End TB Strategy, although five years later than planned.
The global TB incidence rate declined by 14% between 2015 and 2025, well below the strategy’s target of a 50% reduction by 2025. Tuberculosis remains the leading cause of death from a single infectious agent, underlining the scale of the continuing public-health challenge.
Millions Still Miss Timely Diagnosis
Of the estimated 10.6 million people who developed TB in 2025, about 8.4 million were diagnosed. This leaves an estimated 2.2 million people either undiagnosed or unreported, meaning many may not have been reached by the services needed to begin treatment and reduce further transmission.
WHO also reported that only 59% of newly diagnosed patients were tested using a WHO-recommended rapid diagnostic test, short of the global target of 100% by 2027. Rapid testing can help identify TB earlier and guide appropriate treatment, including when drug resistance is suspected.
Drug-resistant TB remains a particularly serious concern. An estimated 370,000 people developed rifampicin-resistant TB in 2025, but only 42% received treatment. Among those treated, use of the WHO-recommended six-month regimen increased from 18% in 2024 to 42% in 2025.
Funding And Research Remain Critical
Domestic TB funding increased to US$5.6 billion in 2025, but WHO says this progress is occurring amid pressure on international health financing. The 30 countries carrying the heaviest burden accounted for 88% of people who developed TB in 2025, highlighting the importance of sustained support in high-burden settings.
Research funding is also far below the level considered necessary. WHO reported that investment in TB research stood at US$1.2 billion in 2023, less than one quarter of the US$5 billion annual target for 2027. Additional investment is needed to develop and introduce better vaccines, diagnostic tools and treatments.
What WHO Says Must Happen Next
WHO is urging governments and partners to protect and increase sustainable funding, expand prevention and rapid diagnosis, ensure access to effective treatment and accelerate research. Strong health systems are needed to find people with TB, support them throughout treatment and prevent the disease from spreading within communities.
TB is preventable and treatable, but successful control depends on people being diagnosed early and completing the appropriate treatment. Anyone with a persistent cough, fever, night sweats, unexplained weight loss or other concerning symptoms should seek assessment from a qualified health professional rather than attempting self-diagnosis.
The 2026 report presents a mixed picture: deaths are declining and domestic investment is rising, but millions remain undiagnosed and drug-resistant disease continues to expose weaknesses in the global response.
Source: World Health Organization — Global Tuberculosis Report 2026.